Details for Patent: 7,615,573

Which drugs does patent 7,615,573 protect, and when does it expire?

Patent 7,615,573 protects CERDELGA and is included in one NDA.

This patent has thirty-eight patent family members in thirteen countries.

Summary for Patent: 7,615,573

Title:	Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Abstract:	Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
Inventor(s):	Siegel; Craig (Woburn, MA), Shayman; James A. (Ann Arbor, MI), Nelson; Carol A. (Westford, MA), Harris; David J. (Lexington, MA), Copeland; Diane P. (North Billerica, MA)
Assignee:	The Regents of the University of Michigan (Ann Arbor, MI) Genzyme Corporation (Cambridge, MA)
Application Number:	11/702,425
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,615,573
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,615,573

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes						TREATMENT OF GAUCHER DISEASE TYPE 1

International Family Members for US Patent 7,615,573

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	554082
Austria	555102
Brazil	0211379
Brazil	122015016313